|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-2-12
|
|
pubmed:abstractText |
To investigate whether baseline (before treatment) clinical variables and tumour specimen characteristics (including the androgen receptor, AR) from patients with castrate-resistant metastatic prostate cancer can be used to predict the time to prostate cancer-specific mortality and overall survival, as AR levels in prostate cancer have been associated with disease progression, including prostate-specific antigen (PSA) recurrence and systemic metastasis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1464-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
462-7
|
|
pubmed:meshHeading |
pubmed-meshheading:19624594-Aged,
pubmed-meshheading:19624594-Androgens,
pubmed-meshheading:19624594-Epidemiologic Methods,
pubmed-meshheading:19624594-Humans,
pubmed-meshheading:19624594-Male,
pubmed-meshheading:19624594-Middle Aged,
pubmed-meshheading:19624594-Neoplasm Metastasis,
pubmed-meshheading:19624594-Neoplasm Proteins,
pubmed-meshheading:19624594-Neoplasms, Hormone-Dependent,
pubmed-meshheading:19624594-Orchiectomy,
pubmed-meshheading:19624594-Prostatectomy,
pubmed-meshheading:19624594-Prostatic Neoplasms,
pubmed-meshheading:19624594-Receptors, Androgen,
pubmed-meshheading:19624594-Time Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.
|
|
pubmed:affiliation |
Aureon Laboratories, Yonkers, New York, NY, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
